Aldosterone-Blocking Pill Shows Dual Benefit for CKD Patients with Hypertension
An experimental aldosterone synthase inhibitor, baxdrostat, lowered systolic BP by 8.1 mm Hg more than placebo and cut urine albumin by 55% after 26 weeks in 192 CKD patients with uncontrolled hypertension on standard therapy, hinting at kidney and cardiovascular protection; however, hyperkalemia was more common (41% vs 5%), and serious adverse events were higher (9% vs 3%). Baxdrostat is not FDA-approved, and Phase 3 trials (including BaxHTN and Bax24) are under way, with exploring combinations like baxdrostat plus dapagliflozin.
